Subject Review

Histone Deacetylase Inhibitors: Overview and Perspectives

Milos Dokmanovic, Cathy Clarke, and Paul A. Marks
Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Abstract
Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death. (Mol Cancer Res 2007;5(10):981–9)

Introduction
There is increasing evidence that the 18 histone deacetylases (HDAC) in humans are not redundant in function. The 18 HDACs are classified into three main groups based on their homology to yeast proteins. Class I includes HDAC1, HDAC2, HDAC3, and HDAC8 and have homology to yeast RPD3. HDAC4, HDAC5, HDAC7, and HDAC9 belong to class II and have homology to yeast HDAC1. HDAC6 and HDAC10 contain two catalytic sites and are classified as class IIa, whereas HDAC11 has conserved residues in its catalytic center that are shared by both class I and class II deacetylases and is sometimes placed in class IV (refs. 1, 2; Table 1). These HDACs contain zinc in their catalytic site and are inhibited by compounds like trichostatin A (TSA) and vorinostat [suberoylanilide hydroxamic acid (SAHA)]. This review focuses on the activities of these zinc-containing HDACs. The class III HDACs include sirtuins, have homology to yeast Sir2, and have an absolute requirement for NAD\(^+\); they do not contain zinc in the catalytic site and are not inhibited by compounds like TSA or vorinostat.

HDACs are known as HDACs because histones were considered the most important target of HDACs (3, 4). Phylogenetic analysis indicates that the evolution of HDACs preceded the evolution of histones, suggesting that primary HDAC targets may not be histones (3). To date, more than 50 non-histone proteins have been identified that are substrates for one or another of the HDACs (refs. 4–8; Table 2). These substrates include proteins that have regulatory roles in cell proliferation, cell migration, and cell death. The enzymes may more properly be referred to as “lysine deacetylases” (8).

The sensitivity of tumor cells and relative resistance of normal cells to HDACi such as vorinostat may reflect the multiple defects that make cancer cells less likely than normal cells to compensate for inhibition of one or more prosurvival factors or activation of a pro-death pathway. Vorinostat inhibition of HDACs is relatively rapidly reversible, and we suggest that this provides normal cells with compensatory capabilities that translate into relative resistance to induced cell death, compared with the sensitivity of cancer cells (4).

HDAC Biological Activity
Class I HDACs are mostly localized within the nucleus whereas class II HDACs shuttle between nucleus and cytoplasm (Table 1; refs. 1, 5–17). Knockout analysis of different class I and class II HDAC proteins indicates that class I HDACs play a role in cell survival and proliferation, whereas class II HDACs may have tissue-specific roles. For example, HDAC1 knockout has a general proliferation and survival defect despite increased levels of HDAC2 and HDAC3 activity (10). HDAC1 and HDAC3 enhance hypoxia-inducible factor-1\(\alpha\) stability via direct interaction with the transcription factor (11). HDAC2 modulates transcriptional activity through regulation of p53 binding activity (12). HDAC2 knockout had cardiac defects (13). HDAC4 knockout mice have defects in chondrocyte differentiation (14); HDAC5 and HDAC9 knockouts have cardiac defects (15). HDAC7 knockouts have defects in the maintenance of vascular integrity (9). HDAC7 localization is controlled by its state of phosphorylation; myosin phosphate phosphatase dephosphorylates HDAC7 and promotes its nuclear localization, causing repression of the HDAC7 target Nur77 (16).

It is well established that HDACs catalyze the deacetylation of \(\alpha\)-acetyl lysine that resides within the NH\(_2\)-terminal tail of core histones, but we know little about the sequence specificity of histones that determine the activity of different HDACs. Using a library of fluorogenic tetrapeptide substrates, HDACs
Table 1. HDAC Characteristics

<table>
<thead>
<tr>
<th>Localization</th>
<th>Class I</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC1</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
</tr>
<tr>
<td>HDAC2</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
</tr>
<tr>
<td>HDAC3</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
</tr>
<tr>
<td>HDAC8</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
<td>Nucleus</td>
</tr>
</tbody>
</table>

**Localization:**
- **HDAC1**: Nucleus
- **HDAC2**: Nucleus
- **HDAC3**: Nucleus
- **HDAC8**: Nucleus

**Size (amino acids):**
- HDAC1: 483
- HDAC2: 488
- HDAC3: 428
- HDAC8: 377

**Chromosomal localization:**
- HDAC1: 1p34.1
- HDAC2: 6q21
- HDAC3: 5q31
- HDAC8: Xq13

**Catalytic sites:**
- HDAC1: 1
- HDAC2: 1
- HDAC3: 1
- HDAC8: 1

**Substrates (partial list):**
- HDAC1: Androgen receptor, SHP, p53, MyoD, E2F-1, Stat3
- HDAC2: Glucocorticoid receptor, YY-1, Bcl-6, Stat3
- HDAC3: SHP, YY-1 GATA-1, RelA, Stat3, MEF2D
- HDAC8: CDK9, SP1, PP4c, EST1B

**Tissue distribution:**
- Ubiquitous

**Knockout phenotype:**
- EL, increased histone acetylation, increase in p21 and p27
- Cardiac defect

**Abbreviations:**
- H, heart; SM, skeletal muscle; B, brain; PL, placenta; PA, pancreas; L, liver; K, kidney; S, spleen. EL, embryonic lethal. Stat3, signal transducers and activators of transcription 3; CDK9, cyclin-dependent kinase 9; MMP10, matrix metalloproteinase 10; Hsp90, heat shock protein 90; HIF-1α, hypoxia-inducible factor-1α.

were ranked according to their substrate selectivity: HDAC8 > HDAC1 > HDAC3 > HDAC6 (17).

The acetylation status of the HDAC substrates is a determinant of their structure and, as a consequence, their activity (Table 2; refs. 1, 5-19). For example, HDAC6 was shown to interact with and deacetylate tubulin, causing modulation of cell migration (18, 19). HDAC1, HDAC2, and HDAC3 were shown to coimmunoprecipitate with the ATP-dependent chaperone protein heat shock protein 70 (20). Inhibition or knockdown of HDAC6 induces heat shock protein-90 acetylation and inhibits its chaperone activity (21, 22). The oncoproteins PLAG1 and PLAG2 are targets for deacetylation by HDAC7 (23).

As discussed below (“HDACi: Mechanisms of Action”), one or more pathways may be involved in HDACi-induced transformed cell death, which is a likely consequence of acetylation of multiple substrates of HDAC (Tables 1 and 2). There are still considerable gaps in our knowledge of the biological functions of the different HDACs.

**Histone Acetyl Transferases and HDACs in Cancer**

Several groups of transcription factors have intrinsic histone acetyltransferase activity. These include GCN5-related N-acetyltransferase, MYST, and cAMP response element binding protein (CREB/p300) families (24). Members of GCN5-related N-acetyltransferase family include GCN5, p300/CREB binding protein—associated factors, Elp3, and activating transcription factor-2. MYST family includes monocyte leukemia zinc-finger protein (MOZ), Vbf2/Sas3, Sas2, Tip60, Esa1, and MOF. Histone acetyltransferases and HDACs function within complexes that include multiple histone acetyltransferases, HDACs, transcription coactivators, and corepressors (25).

Alterations in both histone acetyltransferases and HDACs are found in many human cancers (1, 2, 5, 26-34). Individuals with Rubinstein-Taybi syndrome carry a mutation in CREB binding protein that inactivates its histone acetyltransferase activity. Loss of heterozygosity in p300 gene has been described in 80% of glioblastomas, and loss of heterozygosity in CREB binding protein locus has been observed in a subset of lung cancers. CREB binding protein is fused to different proteins: MLL, MOZ, MYST4, and MORF in acute myeloid leukemia (31-34).

Structural mutations in HDACs associated with cancers are rare. However, changes in expression of different HDACs have been reported in various cancers. HDAC2 and HDAC3 proteins are increased in colon cancer samples (1, 2, 5, 27). HDAC1 is increased in gastric cancer, and reduced expression of HDAC5 and HDAC10 is associated with poor prognosis in lung cancer. HDACs are recruited by oncogenic translocation protein complexes in different types of lymphomas and leukemias (28, 29). A truncating mutation of HDAC2 has been discovered in two colon cancer cell lines and two endometrial cancer cell lines (30).

**HDACs, HDACi, and Gene Expression**

The chromatin structure is complex and composed of DNA, histones, and nonhistone proteins. The basic repeating unit of chromatin is the nucleosome, ~146 bp of DNA wrapped around the histone octamer composed of two copies of each of four histones: H2A, H2B, H3, and H4. Posttranslational modifications of histones, including acetylation, phosphorylation, methylation, ubiquitination, and sumoylation, play an important role in regulating gene expression (25, 35). The two groups of enzymes, histone acetyltransferases and HDACs, determine the pattern of histone acetylation. It has been proposed that histone modifications, acting alone, sequentially, or in combination, represent a “code” that can be recognized by nonhistone proteins, which form complexes that are important for regulation of gene transcription (35).

HDACs and histone acetyltransferases do not bind to DNA directly, but rather interact with DNA through multiprotein complexes that include corepressors and coactivators (24, 25). Class I and class II HDACs form multiprotein complexes containing transcription factors with diverse functions, including...
corepressors like Sin3, nuclear receptor corepressor (N-CoR), silencing mediator for retinoic acid and thyroid hormone receptor (SMRT), as well as activators and chromatin-remodeling proteins (25).

Despite the ubiquitous distribution of HDACs in chromatin, HDACi selectively alter a relatively small proportion of expressed genes (2-10%) in transformed cells (36-40). The effect on gene transcription may be a consequence of acetylation of a particular complex of histones and other proteins regulating gene expression. Studies with lymphoid cell lines found that TSA alters only 2% of 340 expressed genes (36). Recent studies using DNA arrays have shown that as many as 7% to 10% genes were altered in their expression in cell lines of diverse origins (37-40). In these studies, roughly similar number of genes are down-regulated and up-regulated by the HDACi. For example, in a study with CEM cells, a total of 2,205 (22.1%) of expressed genes were altered by vorinostat (as defined by at least 1.5-fold change) by 16 h, with roughly similar numbers being up-regulated and repressed (40).

In a multiple myeloma ARP-1 cell line, vorinostat down-regulated genes of the insulin like growth factor-insulin-like growth factor-I receptor and interleukin-6 receptor signaling cascades and antiapoptotic genes such as caspase inhibitors, oncogenic kinases, DNA synthesis and repair enzymes, transcription factors such as E2F-1, subunits of proteasome, and ubiquitin conjugating enzymes (37). Thymidylate synthetase is commonly repressed by HDACi treatment, including TSA (38).

p21 cyclin-dependent kinase inhibitor is one of the most commonly induced genes by HDACi (41). HDACi induction of p21 is independent of p53. It does correlate with a specific increase in histone acetylation of H3K4 in the p21 promoter region. This change did not occur in the histones associated with the promoter regions of the p27 or of the e-globin genes whose expression is not altered by the HDACi. The protein complex associated with the proximal region of p21 promoter includes HDAC1, HDAC2, myc, BAF155, Brg-1, GCN5, p300, and SP1. Vorinostat caused a marked decrease in HDAC1 and myc and recruitment of RNA polymerase II to this complex. These findings suggest that HDACi-induced selective alteration of transcription of a gene may be determined by the composition and configuration of proteins in the transcription factor complex, including HDACs.

HDACi treatment inhibited the induction of IFN-stimulated gene expression with little or no effect on their basal expression (42). Selective inhibition of HDAC6 protein by small interfering RNA attenuated the IFN-induced gene expression response (43).

In addition to inhibiting catalytic sites of HDACs, HDACi caused selective changes in expression of class II HDAC proteins. For example, HDAC7 is selectively down-regulated by at least two structurally different HDACi: vorinostat and depsipeptide (44). Repression of HDAC7 is associated with down-regulation of HDAC7 mRNA and transformed cell growth arrest.

### Regulation of HDACs

Activities of HDACs are regulated on multiple levels, including protein-protein interactions, posttranslational modifications (sumoylation, phosphorylation, and proteolysis), subcellular localization, and availability of metabolic cofactors (25). Regulation of promoter activity of HDAC genes has been studied for certain HDACs. For example, murine HDAC1 promoter is autoregulated by TSA, which involves several sites studied for certain HDACs. For example, murine HDAC1 promoter is selectively down-regulated by at least two structurally different HDACi: vorinostat and depsipeptide (25). Regulation of promoter activity of HDAC genes has been studied for certain HDACs. For example, murine HDAC1 promoter is autoregulated by TSA, which involves several sites studied for certain HDACs. For example, murine HDAC1 promoter is selectively down-regulated by at least two structurally different HDACi: vorinostat and depsipeptide (44). Repression of HDAC7 is associated with down-regulation of HDAC7 mRNA and transformed cell growth arrest.

### Table 1. HDAC Characteristics (Cont’d)

<table>
<thead>
<tr>
<th>HDAC</th>
<th>Class IIA</th>
<th>Class IIB</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC4</td>
<td>Nucleus/cytoplasm</td>
<td>Nucleus/cytoplasm</td>
<td>Nuclear/cytoplasm</td>
</tr>
<tr>
<td>HDAC5</td>
<td>1,084</td>
<td>1,122</td>
<td>Mostly cytoplasm</td>
</tr>
<tr>
<td>HDAC7</td>
<td>Nucleus/cytoplasm</td>
<td>Mostly cytoplasm</td>
<td>Nucleus/cytoplasm</td>
</tr>
<tr>
<td>HDAC9</td>
<td>855</td>
<td>1,011</td>
<td>Mostly cytoplasm</td>
</tr>
<tr>
<td>HDAC6</td>
<td>1,215</td>
<td>7p21-p15</td>
<td>Nucleus/cytoplasm</td>
</tr>
<tr>
<td>HDAC10</td>
<td>669</td>
<td>Xp11.22-23</td>
<td>3p25.2</td>
</tr>
<tr>
<td>HDAC11</td>
<td>22q13.31-q13.33</td>
<td>22q13.31-q13.33</td>
<td>3p25.2</td>
</tr>
<tr>
<td>HDAC4</td>
<td>1,084</td>
<td>1,122</td>
<td>Mostly cytoplasm</td>
</tr>
<tr>
<td>HDAC5</td>
<td>Nucleus/cytoplasm</td>
<td>Mostly cytoplasm</td>
<td>Nucleus/cytoplasm</td>
</tr>
<tr>
<td>HDAC7</td>
<td>855</td>
<td>1,011</td>
<td>Mostly cytoplasm</td>
</tr>
<tr>
<td>HDAC9</td>
<td>1,215</td>
<td>7p21-p15</td>
<td>Nucleus/cytoplasm</td>
</tr>
<tr>
<td>HDAC6</td>
<td>669</td>
<td>Xp11.22-23</td>
<td>3p25.2</td>
</tr>
<tr>
<td>HDAC10</td>
<td>22q13.31-q13.33</td>
<td>22q13.31-q13.33</td>
<td>3p25.2</td>
</tr>
<tr>
<td>HDAC11</td>
<td>3p25.2</td>
<td>3p25.2</td>
<td>3p25.2</td>
</tr>
</tbody>
</table>

**Defects in chondrocyte differentiation**

- Cardiac defect
- Maintenance of vascular integrity, increase in MMP10
- Cardiac defect
HDACi: Chemistry

HDACi can be divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids, and benzamides (Table 2; refs. 1, 5, 50, 51). TSA was the first natural hydroxamate discovered to inhibit HDACs (52). Vorinostat is structurally similar to TSA (53). A series of aminosuberoyl hydroxamic acids have recently been discovered to inhibit HDACs and transform cell proliferation at nanomolar concentrations (54). Vorinostat is the first HDACi to be approved for clinical use by the Food and Drug Administration (4, 55). Vorinostat is a pan-inhibitor of class I and class II HDAC proteins (4). M-Carboxycinnamic acid bishydroxamate is a potent HDACi (53) and is the structural basis for several derivatives including LAQ-824, LBH-589, and a sulfonamide derivative, belinostat (PXD-101; ref. (51). These HDACi inhibit class I and class II HDACs. Panobinostat (LBH-589; Novartis AG) is a cyclic hydroxamic acid analogue of M-carboxycinnamic acid bishydroxamate. IF2357 (Italfarmaco SpA) is a cyclic peptide mimic linked by an aliphatic chain to a hydroxamic acid, which is active at millimolar concentrations (59).

The cyclic peptide class is a structurally complex group of HDACi, which includes the natural product depsipeptide (Romidepsin, FK-228, Gloucester Pharmaceutical Inc.), apicidin, and the cyclic hydroxamic acid–containing peptide group of molecules, all active at nanomolar concentrations (58). FK-228 is a prodrug of an active agent, red FK. Among newer HDACi is a cyclic peptide mimic linked by an aliphatic chain to a hydroxamic acid, which is active at millimolar concentrations (59).

The aliphatic acids, such as butyrate, phenylbutyrate, and valproic acid, are relatively weak inhibitors of the HDACs, with activity at millimolar concentrations (5, 8, 51). Both valproic acid and phenylbutyrate are drugs that have been in the market for non-oncological uses and were recently shown to have activity as HDACi. AN-9 (pivaloyloxymethyl butyrate; Titan Pharmaceutical, Inc.) is a novel prodrug of butyric acid (51). NOX-275 (MS-275; Syndax Pharmaceutical Inc.) is a synthetic benzamide derivative. MGCD0103 (Methylgene Inc. Pharmion Corp.) is dihydromidamide salt of a substituted 2-aminophenyl benzamide (60). Some HDACi show relative selectivity in the HDACs inhibited (Tables 1 and 3). For example, MS-275 preferentially inhibits HDAC1 compared

### Table 2. Protein Substrates of HDACs (Partial List)

<table>
<thead>
<tr>
<th>Functional Group</th>
<th>Protein</th>
<th>HDAC Implicated</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural protein</td>
<td>α-Tubulin</td>
<td>HDAC6</td>
<td>(19)</td>
</tr>
<tr>
<td>Chaperone protein</td>
<td>Hsp90</td>
<td>HDAC6</td>
<td>(84)</td>
</tr>
<tr>
<td>DNA binding nuclear receptors</td>
<td>Androgen receptor</td>
<td>HDAC1</td>
<td>(83)</td>
</tr>
<tr>
<td></td>
<td>Glucocorticoid receptor</td>
<td>HDAC2</td>
<td>(86)</td>
</tr>
<tr>
<td></td>
<td>Estrogen receptor α</td>
<td>ND</td>
<td>(87)</td>
</tr>
<tr>
<td></td>
<td>SHP</td>
<td>HDAC1, HDAC3, HDAC6</td>
<td>(88)</td>
</tr>
<tr>
<td>DNA binding transcription factors</td>
<td>p53</td>
<td>HDAC1</td>
<td>(89)</td>
</tr>
<tr>
<td></td>
<td>p73</td>
<td>ND</td>
<td>(90)</td>
</tr>
<tr>
<td></td>
<td>MEF2D</td>
<td>HDAC3</td>
<td>(91)</td>
</tr>
<tr>
<td></td>
<td>GCMa</td>
<td>HDAC1, HDAC3, HDAC4, HDAC5</td>
<td>(92)</td>
</tr>
<tr>
<td></td>
<td>YY1</td>
<td>HDAC1, HDAC2, HDAC5</td>
<td>(93)</td>
</tr>
<tr>
<td></td>
<td>GATA-1</td>
<td>HDAC3, HDAC4, HDAC5</td>
<td>(94)</td>
</tr>
<tr>
<td></td>
<td>GATA-2</td>
<td>HDAC3, HDAC5</td>
<td>(95)</td>
</tr>
<tr>
<td></td>
<td>GATA-3</td>
<td>ND</td>
<td>(96)</td>
</tr>
<tr>
<td></td>
<td>MyoD</td>
<td>HDAC1</td>
<td>(97)</td>
</tr>
<tr>
<td></td>
<td>E2F-1</td>
<td>HDAC1</td>
<td>(98)</td>
</tr>
<tr>
<td></td>
<td>E2F-2</td>
<td>ND</td>
<td>(89)</td>
</tr>
<tr>
<td></td>
<td>E2F-3</td>
<td>ND</td>
<td>(89)</td>
</tr>
<tr>
<td></td>
<td>RelA (in NF-κB)</td>
<td>HDAC3</td>
<td>(99)</td>
</tr>
<tr>
<td></td>
<td>PLAG1, PLAG2</td>
<td>HDAC7</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td>Bcl-6</td>
<td>HDAC2</td>
<td>(100)</td>
</tr>
<tr>
<td></td>
<td>c-Myc</td>
<td>ND</td>
<td>(89)</td>
</tr>
<tr>
<td></td>
<td>EKLF</td>
<td>ND</td>
<td>(89)</td>
</tr>
<tr>
<td></td>
<td>HIF-1α</td>
<td>ND</td>
<td>(101)</td>
</tr>
<tr>
<td>Transcription coregulators</td>
<td>Rb</td>
<td>ND</td>
<td>(102)</td>
</tr>
<tr>
<td></td>
<td>PGC-1α</td>
<td>Class III</td>
<td>(103)</td>
</tr>
<tr>
<td></td>
<td>DEK</td>
<td>ND</td>
<td>(104)</td>
</tr>
<tr>
<td>Chromatin remodeling</td>
<td>HMG-A1</td>
<td>ND</td>
<td>(105)</td>
</tr>
<tr>
<td></td>
<td>HMG-B1</td>
<td>ND</td>
<td>(105)</td>
</tr>
<tr>
<td></td>
<td>HMG-B2</td>
<td>ND</td>
<td>(105)</td>
</tr>
<tr>
<td></td>
<td>HMG-N2</td>
<td>ND</td>
<td>(106)</td>
</tr>
<tr>
<td></td>
<td>HMG(Y)</td>
<td>ND</td>
<td>(106)</td>
</tr>
<tr>
<td></td>
<td>SRY</td>
<td>HDAC3</td>
<td>(107)</td>
</tr>
<tr>
<td>Signaling mediators</td>
<td>Stat3</td>
<td>HDAC1, HDAC2, HDAC3</td>
<td>(108)</td>
</tr>
<tr>
<td></td>
<td>Smad7</td>
<td>HDAC1, HDAC3, HDAC2, HDAC5, HDAC6</td>
<td>(109)</td>
</tr>
<tr>
<td></td>
<td>IRS-1</td>
<td>ND</td>
<td>(110)</td>
</tr>
<tr>
<td></td>
<td>β-Catenin</td>
<td>ND</td>
<td>(111)</td>
</tr>
<tr>
<td>DNA repair enzymes</td>
<td>Ku70</td>
<td>ND</td>
<td>(112)</td>
</tr>
<tr>
<td></td>
<td>WRN</td>
<td>ND</td>
<td>(113)</td>
</tr>
<tr>
<td>Nuclear import</td>
<td>Importin-α7</td>
<td>ND</td>
<td>(114)</td>
</tr>
</tbody>
</table>

Abbreviations: ND, not determined. HMG, high mobility group.
with HDAC3 and has little or no effect against HDAC6 and HDAC8. Two novel synthetic compounds, SK7041 and SK7068, preferentially target HDAC1 and HDAC2. A small molecule, tubacin, selectively inhibits HDAC6 activity and causes accumulation of acetylated tubulin, but does not affect acetylation of histones and does not inhibit cell cycle progression (61). It remains to be determined whether selective inhibition of HDACs would be advantageous over pan-inhibition of HDACs in cancer treatment (4, 50, 62).

**Combination of HDACi with Other Antitumor Agents**

HDACi is synergistic or additive with different antitumor agents, including radiation therapy (1), chemotherapy, differentiation agents, epigenetic therapy, and new targeted agents (1, 5, 63-65). Chemotherapeutic agents with additive or synergistic effects with HDACi therapy include antitubulin agent docetaxel; topoisomerase II inhibitors doxorubicin, etoposide, and ellipticine; and DNA cross-linking reagent cisplatin (1, 5, 51). Some of the new targeted agents include Bcr-Abl inhibitor imatinib, heat shock protein-90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (64), proteasome inhibitor bortezomide (PS-341; ref. 65), and Her2 receptor inhibitor trastuzumab (Herceptin). Elucidation of downstream antitumor pathways engaged by HDACi may enable the development of more effective therapeutic strategies with these drugs (5, 8, 51).

**HDACi in Clinical Trials**

At least 12 different HDACi are undergoing clinical trials as monotherapy or in combination with retinoids, Taxol, gemcitabine, radiation, etc., in patients with hematologic and solid tumors, including lung, breast, pancreas, renal, and bladder cancers, melanoma, glioblastoma, leukemias, lymphomas, and multiple myeloma (5, 51, 64; Table 2). There are well over 100 clinical trials ongoing with HDACi as monotherapy or in combination therapy. The available results of these clinical trials have recently been reviewed (51). From these studies, one can conclude that HDACi, including vorinostat, depsipeptide, LBH-589, PDX-101, and several others, have activity in hematologic malignancies and solid tumors at doses that are well tolerated by patients.

Information about ongoing studies are available at several websites.1

**Hydroxamic Acids**

Vorinostat (SAHA) is the first of the new HDACi to be approved by the Food and Drug Administration for clinical use in cancer patients for the treatment of cutaneous T-cell lymphoma. In a phase II clinical trial, 33 previously treated patients with refractory cutaneous T-cell lymphoma received orally administered vorinostat up to 400 mg od. Partial responses were observed in 8 (24.2%) patients and 14 of 31 (45.2%) patients had relief from pruritus. Vorinostat-related toxicities included anemia, thrombocytopenia, fatigue, and diarrhea (55). Vorinostat was evaluated in phase I clinical trials as an i.v. (66) and orally administered drug (67). Patients included those with hematologic (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and multiple myeloma) and solid malignancies (prostate, bladder, breast, colon, ovarian, and renal). In both trials, there was evidence of significant antitumor activity at doses that were well tolerated by patients. In the study with oral formulation, 30% of patients remained on study for 4 to >37 months. Of those patients, there was one complete response in a diffuse large B-cell lymphoma patient and three partial responses in de novo diffuse large B-cell lymphoma, laryngeal cancer, and papillary thyroid cancer patients. Stable disease was seen in all other responsive patients (30% of original patient cohort; ref. 67).

In the clinical trial with oral vorinostat in pretreated mesothelioma patients, 2 of 13 patients had a partial remission (68). More than 50 clinical trials with combination therapy with vorinostat and various agents (carboplatin, paclitaxel, 5-fluorouracil, etc.) in patients with advanced hematologic and solid tumors are in progress (see websites indicated earlier).

LBH-589 is a hydroxamic acid–based HDACi with a structure similar to vorinostat (Table 3). It is in phase I clinical trials for cutaneous T-cell lymphoma as an oral agent administered on a Monday, Wednesday, Friday schedule. It has a longer half-life than vorinostat. Responses were seen in 6 or 10 patients including two complete responses and one partial response. Toxicities were similar to those observed with vorinostat (51).

ITF2357, another hydroxamic acid–based HDACi, is in clinical trial for refractory multiple myeloma (56).

PXD-101 (Bellinostat) has completed a phase I open-label study with i.v. administration and is undergoing further studies with an oral preparation. Preliminary data indicate that the oral doses are well tolerated and antitumor activity in the form of stable disease in patients with advanced cancer was observed (57).

**Cyclic Peptides**

Depsipeptide (Romidepsin; Table 3) is currently in phase II clinical trials including a pivotal trial in cutaneous T-cell lymphoma and peripheral T-cell lymphomas (51, 63). In cutaneous T-cell lymphoma, an objective response was observed in 10 of 28 evaluable patients, including 3 complete responses and 7 partial responses, for an overall response rate of 36%. Adverse events included myelotoxicity, nausea, vomiting, and cardiac dysrhythmias.

Depsipeptide is also in clinical trials as monotherapy and in combination therapy with various antitumor agents in patients with hematologic and solid malignancies (63).

**Benzamides**

MS-275 (Table 2) is in clinical trials as an oral preparation with evidence of antitumor activity (51).

Another benzamide-based HDACi, MGCD0103 is in early combination trials (60).

**Aliphatic Acids**

Aliphatic acids such as valproic acid (VA) or AN-9 (Table 3) generally are weaker HDACi than hydroxamic acid– or cyclic peptide–based agents. Valproic acid had some therapeutic effect as monotherapy in myelodysplastic syndromes (69).
Clinical trials with phenylacetate have generally shown little anticancer activity (5, 51, 70).

**HDACi: Mechanisms of Action**

The mechanisms of HDACi-induced transformed cell growth arrest and cell death are complex and not completely elucidated (1, 4-8). HDACi can cause the accumulation of acetylated histones and many nonhistone proteins that are involved in regulation of gene expression, cell proliferation, cell migration, and cell death.

Normal cells are relatively resistant to HDACi-induced cell death (71, 72), whereas a broad variety of transformed cells are sensitive to inhibitor-induced cell death. Vorinostat and other HDACi can induce transformed cell cycle arrest and terminal cell differentiation (2), cell death by activating the intrinsic apoptotic pathway (73), activating the extrinsic apoptotic pathway, mitotic failure, autophagic cell death, polyploidy, and senescence, and reactive oxygen species--facilitated cell death (8). HDACi can block angiogenesis (5-8). The induction of a particular response in

<table>
<thead>
<tr>
<th>Table 3. HDACi (Partial List)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
</tr>
<tr>
<td>Hydroxamates</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Cyclic peptide</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Aliphatic Acids</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Benzamides</td>
</tr>
</tbody>
</table>

Abbreviations: GA, growth arrest; TD, terminal differentiation; A, apoptosis; AI, cell death by activating intrinsic apoptotic pathway; AE, cell death by activating extrinsic apoptotic pathway; MF, mitotic failure; AU, autophagic cell death; S, senescence; PP, polyploidy; ROS-CD, reactive oxygen species–facilitated cell death; N/A, not available; CBHA, M-carboxycinnamic acid bishydroxamate; CTCL, cutaneous T-cell lymphoma; CTCL, peripheral T-cell lymphoma.
transformed cells seems to depend on “cell content” (i.e., molecular changes in the transformed cell), the HDACi used, and the concentration of and time of exposure to the inhibitors.

HDACi have been discovered that are up to 2 or more logs more active than vorinostat in inhibiting partially purified class I and class II HDACs (Table 1; ref. 4). These more active HDACi have generally been more toxic in in vivo studies in tumor-bearing animals. Vorinostat has only medium potency in inhibiting HDACs (4). This reflects its binding constant and the relatively rapid reversibility of its binding to HDACs.

Compounds that are more strongly bound are released from the binding pocket more slowly in a first-order process unaffected by the concentration of free ligand. Stronger binding might lead to a more lasting inhibition of the activity of HDAC in both normal and cancer cells and could cause undesirable effects. Vorinostat binding to HDACs is sufficient to cause accumulation of acetylation of target proteins, and its relatively rapid release from the binding site allows for some level of deacetylation activity.

Essentially all cancer cells have multiple defects in expression and/or structure of proteins that regulate cell proliferation, migration, and death. Among transformed cells, even of the same clinical diagnosis, there is heterogeneity in the multiple defects (73). The plurality of target proteins of HDAC and, thus, of HDACi, such as vorinostat, may be important for the efficacy of these agents against a broad spectrum of hematologic and solid tumors. The relative resistance of normal cells to vorinostat, we suggest, could be owing to the ability of normal cells to recover from the inhibitor because of its rapidly reversible binding in intervals of nonexposure to the drug.

Consistent with this hypothesis is the observation that in patients receiving vorinostat, once a day (half-life, ∼4-6 h), there is accumulation of acetylated histones in normal peripheral mononuclear cells, which is transient (demonstrable up to 8-10 h following the oral dose; ref. 67). This vorinostat-induced transient accumulation of acetylated histones in normal cells occurred in patients with significant anticancer effects, but had no detectable effect on leukocyte count.

Non-Oncologic Potential of HDACi

There is growing evidence that HDACi have potential therapeutic application in nonmalignant diseases. For example, several reports indicate that HDACi have selective anti-inflammatory and specific immune modulator activity (74, 75). HDACi, in preclinical studies, have been reported to have therapeutic benefit in neurodegenerative diseases associated with memory impairment (76). HDACi have been shown to slow the progression of Huntington-like syndrome in mice (77, 78). HDACi are potent inducers of γ globin gene expression, which has implications for treatment of sickle-cell anemia (79). TSA has been shown to cause functional and morphologic recovery of dystrophic muscles in mice (80). Vorinostat has antiinflammatory activity in mouse and rat models (81). HDACi can modulate stem cell survival and mobilization in in vitro studies (82). Valproic acid can activate latent HIV infection, and thus HDACi may have a therapeutic use in treating HIV (83).

Conclusions and Perspectives

Vorinostat is the first HDACi to be approved for clinical use in treating patients with malignancy (e.g., cutaneous T-cell lymphoma; ref. 4, 55). The molecular basis for the antitumor effects of vorinostat and other HDACi is not completely understood. It is not clear if more selective targeting of a particular HDAC as compared with pan-HDAC (such as vorinostat) will result in improved HDACi efficacy (4, 62).

We present a hypothesis for the basis of the sensitivity of transformed cells and relative resistance of normal cells to vorinostat. We suggest that the rapid reversal of the binding of the HDACi to its target may provide normal cells with the ability to compensate for the inhibitory effects of these agents, whereas cancer cells with multiple defects altering proteins regulating cell proliferation, survival, death, and migration are less able to compensate for the effect of the HDACi. This hypothesis, if it has validity, suggests that clinical therapeutic strategies involving intermittent dosing may be a most effective regimen to achieve selective anticancer activity. Further, the multiple protein targets of HDACs and, therefore, of HDACi and the preclinical evidence of synergy and additive activity with many other anticancer agents suggest that a therapeutic strategy using HDACi with other anticancer agents may be most promising.

References

16. Parra M, Mahmoudi T, Verdin E. Myosin phosphatase dephosphorylates


Histone Deacetylase Inhibitors: Overview and Perspectives
Milos Dokmanovic, Cathy Clarke and Paul A. Marks


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/5/10/981

Cited articles
This article cites 112 articles, 49 of which you can access for free at:
http://mcr.aacrjournals.org/content/5/10/981.full.html#ref-list-1

Citing articles
This article has been cited by 82 HighWire-hosted articles. Access the articles at:
/content/5/10/981.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.